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Background. TheMolecular Adsorbent Recirculating System (MARS) has been shown to clear albumin-bound toxins from patients
with liver failure but might cause bleeding complications potentially obscuring survival benefits. We hypothesized that monitoring
clotting parameters and bed-side thromboelastography allows to reduce bleeding complications. Methods. Retrospective analysis
of 25 MARS sessions during which clotting parameters were monitored by a standardized protocol. Results. During MARS
therapy median INR increased significantly from 1.7 to 1.9 platelet count and fibrinogen content decreased significantly from
57 fL−1 to 42 fL−1 and 2.1 g/L to 1.5 g/L. Nine relevant complications occurred: the MARS system clotted 6 times 3 times
we observed hemorrhages. Absent thrombocytopenia and elevated plasma fibrinogen predicted clotting of the MARS system
(ROC 0.94 and 0.82). Fibrinolysis, detected by thromboelastography, uniquely predicted bleeding events. Conclusion. Bed-
side thromboelastography and close monitoring of coagulation parameters can predict and, therefore, help prevent bleeding
complications during MARS therapy.
1. Introduction
Due to limited donor liver availability, only selected patients
with acute or acute-on-chronic liver failure profit from
liver transplantation [1]. The majority of patients receive
supportive therapy, and mortality remains high [2]. Various
artificial liver support systems have been developed and
proposed as bridging therapy until liver function recovers
or a donor organ becomes available [3]. The Molecular
Adsorbent Recirculating System (MARS), a cell-free albumin
dialysis device, has been shown to remove albumin bound
compounds and toxins and to exert a number of beneficial
hemodynamic effects in patients with acute and acute-on-
chronic liver failure [4]. However, to date, neither MARS
nor any other liver support system has been unequivocally
proven to alter clinical outcomes such as survival, a con-
clusion based on a meta-analysis [5] and yet unpublished
multicenter clinical trials (HELIOS study, RELIEF trial;
European Association for the Study of the Liver 2010).
Bleeding disorders are a major concern in all patients
with liver failure [6]. MARS involves an extracorporeal blood
circuit through a filter. This can lead to activation of platelets
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and the coagulation system [7]. Recent reports describe
an association of severe and potentially fatal bleeding
complications with MARS therapy [8–10].
Patients’ age, vasopressor therapy, pretreatment INR,
fibrin D-dimer and fibrinogen concentrations [8], factor
VIII, von Willebrand factor and severely altered thromboe-
lastography parameters [9] were identified as risk factors for
bleeding complications during MARS therapy. However, the
predictive accuracy of each of these parameters was relatively
low, limiting their use during individual MARS sessions in
individual patients.
Routine coagulation parameters are not useful in pre-
dicting bleeding complications in general. They cannot be
used reliably to monitor coagulopathy during MARS due
to the delay until the results are available at the bed-
side. Thromboelastography is successfully used for managing
coagulopathy during liver transplantation [11]. The role
of bed-side monitoring of coagulation using thromboelas-
tography during MARS has been discussed controversially
[9, 10]. Although thromboelastography parameters were
found to be altered by MARS therapy, the large variability
of all parameter tested precluded the tests from accurately
identifying patients at risk [9].
In another study using thromboelastography to monitor
patients receiving MARS no bleeding episodes occurred.
Thus, its value in predicting complications could not be
estimated [10].
We hypothesized by combining thromboelastography
and determination of standard clotting parameters, coagu-
lopathy could be recognized very early during the MARS
sessions. In patients receivingMARS we thus performed bed-
side monitoring of coagulation using a standardized protocol
for thromboelastography and determination of standard
clotting parameters. This allowed to obtain coagulation
parameters timely linked to the MARS sessions. We postu-
lated that bleeding complications could thus be reduced by
either stopping MARS and/or substituting coagulation prod-
ucts even before occurrence of bleeding complications. In
this post hoc analysis we investigated if and which parameters
might allow to identify complicated MARS sessions.
2. Patients and Methods
2.1. Patients. At our institution, the largest tertiary hospital
in Switzerland, patients with acute liver failure (ALF), acute-
on-chronic liver failure (AoCLF), intractable pruritus of hep-
atic origin, or toxic drug accumulation because of impaired
hepatic clearance are eligible for MARS treatment. A clinical
protocol had been approved by the local Ethics Committee.
Potential candidates were identified by the primary physician
and were then evaluated for initiation ofMARS therapy by an
interdisciplinary team consisting of intensive care physicians
(R. A. Schuepbach, R. Stocker, M. Be´chir, E. B. Bachli) and
hepatologists (B. Mu¨llhaupt, E. L. Renner). After approval
for MARS therapy by the interdisciplinary team, informed
consent was obtained from all patients (or their next of
kin). The present trial was approved by the local Ethics
Committee, and conducted in accordance to the declaration
of Helsinki.
2.2. Data Collection. Twenty five MARS sessions performed
in 5 patients at the University Hospital Zurich, Switzer-
land, were retrospectively analyzed. Data on coagulation
and thrombelastography had been prospectively collected
according to a protocol specified below. The protocol was
formulated by the above-mentioned physicians with the aim
of preventing complications in patients receiving MARS.
Data was retrospectively extracted from (i) the electronic
hospital data base (KISIM, Cistec, Switzerland) capturing
laboratory and clinical data, (ii) from the RoTeg thromboe-
lastography analyzer and (iii) the paper chart of each patient
containing all nursing notes and hand written ICU flow
sheets which included demographics, diagnosis of underly-
ing liver disease, indication forMARS therapy, time/duration
of MARS sessions, pretreatment Child-Pugh [12], MELD
[13], and SAPS II [14] sores, mechanical ventilation and/or
vasopressor support, pre, on- and post-treatment laboratory
parameters, time (relative to MARS), quantity and entity of
transfusions and concomitant administration of medications
eventually interfering with coagulation and/or clotting tests
such as heparin.
The following outcome data was extracted, change in
clotting parameters between a baseline sample collected
immediately prior to starting MARS and a sample drawn
after one hour of MARS and at the end of the MARS, overt
bleeding during MARS from any site, requirement/amount
of transfusions of red cells, platelets and coagulation prod-
ucts (FFP, fibrinogen, clotting factors), duration of MARS
sessions and cause of premature termination, as well as death
within 30 days of MARS treatment.
2.3. MARS Dialysis Therapy. The Molecular Adsorbent
Recircultating System (MARS; Teraklin AG, Rostock, Ger-
many) was utilized according to the manufacturer’s instruc-
tions. The system was connected to a PRISMA (Gambro
Hospal, Glattbrugg, Switzerland) hemofilter pump. The
extracorporeal blood circuit was primed with unfractionated
heparin (5000 IU) during filling and thereafter flushed with
0.9% NaCl. Then MARS was connected to a large double
lumen dialysis catheter in either subclavian or jugular
position. Blood flow was set at 120 mL/min, flow within the
albumin circuit of theMARS system at 150mL/min, dialysate
flow at 33mL/min and net fluid balance at zero. In patients in
whom bleeding risk was felt to be low or who had thrombotic
problems with extracorporeal devices such as hemofil-
ters either 400 IU/h of unfractionated heparin or Flolan
(epoprostenol sodium; GlaxoSmithKline, Mu¨nchenbuchsee,
CH) was infused directly into the extracorporeal circuit
(immediately prior to the MARS filter). If tolerated and
feasible, at least three initial MARS sessions of up to 10 hours
duration were performed (Table 1). Continuation depended
on the laboratory and clinical evolution of the patient,
as judged by the interdisciplinary team and the primary
responsible physicians.
2.4. Laboratory Methods and Standardisation of Thromboe-
lastography. As a consequence of our previous observation
study [8] clotting parameters were closely monitored in
Critical Care Research and Practice 3
Table 1: Duration of individual MARS sessions, usage of anticoag-
ulants and observed complications.
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all patients receiving MARS using a standardized protocol.
Thus, venous blood was collected from all patients imme-
diately before, and 1, 2, and 4 hours after the start, as well
as after completion of each MARS session using EDTA,
heparin and plain vacutainer tubes (Becton-Dickinson, San
Jose, CA, USA), as required for the different analysis. Samples
were analyzed within 2 hours of collection. Blood counts,
prothrombin time (PT with international standardize ratio
INR), activated partial thromboplastin time, (aPTT), throm-
bin time (TT), fibrinogen, D-dimer, bilirubin, creatinin,
bilirubin, and C reactive protein (CRP) were determined in
the hospital’s accredited laboratory using standard methods.
Bed-side thromboelastography was performed on a semi
automated device (RoTeg, Pentafarm, Germany) accord-
ing to the manufactures instructions. Blood samples were
collected in EDTA containing vacutainer tubes (Becton-
Dickinson, San Jose, CA, USA). Using the automated pipette
of the RoTeg-device, samples of 300 µL whole blood were
recalcificated by StarTeg (Calciumcholride by Pentapharm,
Germany) after adding InTeg (Pentafarm, Germany), an
aPTT-like activator.
To establish reference values for thromboelastography we
relied on 40 volunteers who had signed an informed consent.
Data was analyzed from 20 men and 20 women (aged 24 to
55 years). All volunteers had completed a standardised health
questionnaire and all laboratory parameters (INR, aPTT,
TT, fibrinogen, D-dimer, platelets, leucocytes, hemoglobin,
600 s
20mm
CT
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60 minutes
Figure 1: Scheme of parameters obtained by thromboelastography:
Given are the clotting time (CT), the time in seconds passing
until initial clot formation (CFT), the time in seconds passing
until a strength of the clot of 20mm is reached, the maximal
clot firmness (MCF), an arbitrary unit in mm which reflects the
maximal clot strength representing the interaction of fibrin and
platelets and the remaining relative clot firmness after 60 minutes
(Lys 60; %), representing fibrinolysis. Time is presented on the
x-axis (horizontal; grid 600 seconds), clot strength on the y-axis
(vertical; grid 20, resp., 40mm).
creatinin, bilirubion, CRP and ferritin) were within nor-
mal limits. In each volunteer thromboelastography was
performed in duplicate and if inter-individual differences
exceeded 5%, the analysis was repeated. Normal range of
parameters was defined as values between the 2.5 and the
97.5 percentile. Normal ranges were established for the
clotting time (CT; i.e., the time in seconds between adding
calcium to the blood sample and detection of clot formation
to begin), clot firmness (CMF; i.e., an historical arbitrary
unit in millimetres reflecting the clot strength; basing on the
impedance of pin movement), clot formation time (CFT; i.e.,
the time that had passed (in seconds) between detecting of
clot formation to begin and achievement of a clot strength
with 20 mm amplitude), and the relative firmness of the clot
after 60 minutes in relation to the maximal firmness (in %;
Lys 60′) (Figure 1). Normal ranges of each parameter are
summarized in Table 2 and are consistent with the values
given by the manufacture.
In a subset of patients frozen plasma samples (stored
at −80◦C) were analyzed for prothrombin fragments
(Enzygnost∗F1 + 2, Dade Behring Marburg GmbH, Ger-
many) and the endogenous calibrated thrombin potential
(ETP) was determined using the Thrombinoscope Package
(software, reagents, fluorometer; ThrombinoScope; Maas-
tricht, NL). Measurements were done according to the
manufacturer’s instructions [15].
2.5. Missing Values. Analysis for each clotting parameter and
each session were performed if at least one parameter was
available from before starting MARS treatment (up to 6
hours before MARS start), a second obtained during a time
window of 30 to 60 minutes after MARS was started and
a third obtained in a time window of 0 to 6 hours after
MARS was discontinued. During two uneventful sessions
(patient no. 2) thromboelastography was not performed as
a deviation from the standard operating procedure.
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Table 2: Reference values of activated Thromboelastography.
Parameter 2.5 percentile 97.5 percentile Median (min./max.)
CT (seconds) 110.1 234.3 136 (103/257)
CFT (seconds) 42.2 128.8 74 (38/142)
MCF (mm) 47.1 67.0 58 (45/70)
Lys 60 (%) 98 89 96 (98/88)
2.6. Data Analysis and Statistics. Data are shown as line plots
(dots present individual data pairs linked by lines), box and
whisker plots (with the box containing the middle 50% of
the data and being divided up by the line representing the
median, whiskers extending to 1.5 times the interquartile
range above and below the 75th and 25th percentile, and
closed dots representing outliers), or dot plots (mean ±
standard deviation). For comparisons of two groups of either
paired or unpaired samples we used the nonparametric
Wilcoxon analysis and for 3 sample comparison the non-
parametric Kruskal-Wallis one-way ANOVA on ranks. If
the ANOVA analysis was significant, Bonferroni pair-wise
group comparison was performed. Statistical analyses and
data editing and presentation were performed using NCSS
(NCSS 2007; Kaysville, Utah) and SPSS (SPSS Statistics 17.0;
Chicago, Illinois) software packages.
3. Results
3.1. Patients and Baseline Characteristics. Baseline charac-
teristics of the 5 patients undergoing a total of 25 MARS
sessions are summarized in Table 3. Three of the five patients
suffered from a lowered level of consciousness due to
markedly impaired liver function. They required intuba-
tion for airway protection, were mechanically ventilated
and required intermittent vasopressor support during the
majority of theMARS sessions. Three of the five patients died
within 30 days of MARS therapy. The 2 other patients (the
patient with primary biliary cirrhosis and the patient with
severe intoxication) survived more than 90 days after MARS
therapy.
3.2. Efficacy of MARS Treatment. Serum concentrations
of creatinin, bilirubin arterial ammonium and CRP were
determined before and after each MARS session. As reported
previously, serum creatinin and bilirubin were significantly
cleared by MARS (Figure 2) [8]. Serum ammonia and CRP
were unaffected by MARS (not shown).
3.3. Complications during MARS Treatment and Baseline
Clotting Parameters. Complications due to MARS treatment
occurred during 9 of the 25 sessions (36%). Bleeding
from catheter insertion sites necessitating termination of
the MARS sessions occurred during 3 sessions (patient
no. 2, session 1; patient no. 4, session 6 and 7). MARS
was definitively discontinued in patient no. 4. In patient
no. 2, MARS therapy was resumed after one week and
unfractionated heparin was omitted due to previous bleeding
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Figure 2: MARS therapy efficiently clears serum creatinin and
bilirubin. Evolution of the parameters serum creatinin and bilirubin
during MARS therapy. Each line represents a pair of values
from an individual MARS treatment session. Gray dots represent
values from uneventful MARS session, black open circles sessions
complicated by device clotting and black triangles sessions with
bleeding complications. Closed black circles connected by a thick
black line indicate mean values. Significant P values are indicated,
sessions analysed (n = 25), of which (n = 16) were uneventful,
(n = 3) were complicated by bleeding and (n = 6) by clotting of the
MARS filter system.
events; however, the two subsequent sessions (2 and 3) had to
be stopped prematurely because of clotting within the MARS
filter system. In addition, filter clotting lead to shortening
of session 2 and 4 in patient no. 3. Filter clotting happened
despite application of 400 IU/h of unfractionated heparin
(patient no. 5) or of epoprostenol sodium (patient no. 3;
Table 1).
3.4. Prediction of Complicated MARS Sessions. In order to
explore predictors for bleeding or clotting events dur-
ing MARS, we compared various coagulation parameters
prior to sessions with and without events. None of the
parameters analysed at baseline (INR, aPTT, TT, fibrinogen
content, D-dimer, platelet count, CT, CFT, MCF, or Lys
60′) were significantly associated with developing bleeding
complications. In contrast, fibrinogen content and platelet
counts were significantly higher prior to sessions that were
later complicated by MARS filter clotting (Figure 3(a)).
The predictive value of a parameter can be estimated by
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Table 3: Demographics and laboratory data prior to MARS treatment.
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1 w 45 ALF1 5 10 13 69 3 306 56 102 1.7 60
2 w 50 AoCLF2 7 10 22 33 5 400 145 58 1.8 108
3 w 41 Pruritus3 4 5 6 7 0 7 70 1 291
4 m 63 HRS4 7 11 13 55 3 125 204 56 1.8 35
5 m 82 Intox5 2 6 6 61 3 4 97 12 1 264
median 50 5 10 13 55 3 108 97 57 1.75 108
1
Acute liver failure, due to liver infiltration by lymphoma.
2Acute on chronic liver failure, the underlying liver disease was nonalcoholic steatohepatitis triggered by infection.
3Primary biliary cirrhosis with refractory pruritus.
4Hepatorenal syndrome due to Child-Pugh C cirrhosis attributable to alcoholic liver disease.
5Severe intoxication with clorazepate.
6–8According to the following publications: 6: to [12]; 7: to [13]; 8: to [14].
9Number of organs/systems requiring pharmacologic and/or mechanical support.
10–14Normal value/range: 10: <17 µmol/L; 11: 70–150 µmol/L; 12: <33 µmol/L; 13: <1.2; 14: 143–400 × 109/L.
calculation of the area under the curve (AUC) in receiver
operator curves (ROC). AUCROC were found to be 0.94 for
fibrinogen and 0.82 for platelets (Figure 3(b)). In our cohort,
a fibrinogen content of 2.5 g/L or more was found to predict
filter clotting with 100% sensitivity and 80% specificity.
Platelet counts exceeding 150 fL−1 still had a 80% sensitivity
and a specificity of 80%.
3.5. Changes in Clotting Parameters during MARS Therapy.
INR, aPTT, TT, fibrinogen content, D-dimer, platelets and
the thromboelastography parameter CT, CFT, MCF and
Lys 60′ were all found to significantly deteriorate around
2 hours of MARS therapy (Figure 4(a)). In most sessions
the parameters either normalized spontaneously or due to
transfusion of clotting substrates or platelets. The latter is the
reason why the focus of our analysis is on the initial phase of
MARS therapy.
To test if clotting parameters were differently affected by
MARS in the subgroup of MARS sessions without complica-
tions, with bleeding complications and sessions complicated
by clotting events ANOVA was performed. ANOVA was
significant for changes in TT and hyperfibrinolysis (Lys 60′).
Bonferroni pairwise comparisons revealed that the increase
of TT duringMARSwas significant in the subgroup ofMARS
sessions complicated by device clotting events (Figure 4(b)).
Device clotting occurred despite the usage of heparin (2 out
of 6 sessions) or epoprostenol (2 out of 6 sessions; Table 1).
The parameter indicating hyperfibrinolysis (Lys 60′) was
significantly affected by MARS in sessions complicated by
bleeding events (Figure 4(c)). For all other parameters (INR,
aPTT, fibrinogen content, D-dimer, platelets CT, CFT, MCF
and Lys 60′) no subgroup specific alteration by MARS could
be detected.
3.6. Predicting Bleeding Complications by Monitoring Clotting
Parameters. We expected that hourly monitoring of clotting
parameters during MARS therapy would identify patients
at risk for bleeding complications. After one hour of the
first MARS session in patient no. 2 thromboelastography
revealed signs of fibrinolysis (Figure 5). In view of the yet
unaffected parameters INR, aPTT, TT, fibrinogen content,
D-dimer and platelet count MARS was not discontinued
until when bleeding occurred two hours after startingMARS.
The stopping of MARS treatment together with substitution
of fibrinogen (2 g), fresh frozen plasma (2 units) and platelets
(1 unit) and therapy with tranexamic acid (40mg/kg body
weight) bleeding stopped and clotting parameters improved
reaching baseline values within one hour (Figure 5) of
substitution.
In contrast, monitoring failed to announce the bleeding
complications in patient no. 3. In this patient bleeding
occurred during the sixth and the seventh MARS sessions.
Baseline INR, aPTT, TT, fibrinogen content, D-dimer,
platelet count and thromboelastography parameters were not
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Figure 3: High plasma fibrinogen concentration and lack of thrombocytopenia at baseline predict clotting within the MARS filter system.
(a) Baseline fibrinogen concentrations and platelet counts from individual sessions were grouped into sessions without event (uneventful),
complicated by bleeding episodes and complicated by clotting events within the MARS filter system. (b) Receiver operator curve of baseline
plasma fibrinogen concentration and platelet count for prediction of MARS filter clotting events. Significant P values are indicated, AUCROC
= 0.94 (CI95% 0.74 to 0.99) for fibrinogen, 0.82 (CI95% 0.5 to 0.95) for platelets, respectively, sessions analysed (n = 25), of which (n = 16)
were uneventful, (n = 3) were complicated by bleeding and (n = 6) by clotting of the MARS filter system.
found to significantly differ between the two complicated
and the previous 5 uncomplicated sessions. Despite the close
(hourly) monitoring during MARS therapy, we failed to
anticipate bleeding in this patient because of defibrination
(fibrinogen 0.15 g/L) and bleeding occurred faster then the
first results obtained with our monitoring.
3.7. Prothrombin Activation and Thrombin Potential in
MARS Therapy. To further explore the potential underlying
mechanism driving clotting complications during MARS
therapy we retrospectively quantified F1+2 peptide fragments.
These activation peptides are generated upon the conversion
of prothrombin into thrombin and serve as marker for
thrombin generation. Baseline F1+2 were elevated and found
to slightly decrease under MARS therapy (Figure 6(a)).
Recently an old diagnostic parameter, the “thrombin
potential” which correlates with coagulability and hence pro-
vides insight into the level of bleeding risk [16] has become
relatively easy to determine. In a subset of the patients
the thrombin potential was determined post hoc and was
found to be significantly decreased during MARS in terms of
timing (prolongation of lag time and time to peak) as well
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Figure 4: Clotting parameters deteriorate during MARS therapy: (a) Evolution of the clotting parameters INR, aPTT, TT, plasma fibrinogen
concentration, D-Dimer, platelet count and the thromboelastography parameters CT, CFT, MCF and Lys 60′ during MARS therapy. Each
line represents a pair of values from an individual MARS treatment session. Gray dots represent values from uneventful MARS session,
black open circles sessions complicated by device clotting and black triangles sessions with bleeding complications. Closed black circles
connected by a thick black line indicate mean values. All parameters worsened significantly during MARS sessions, P values are indicated,
n = 16 to 25. (b) and (c) Sessions of MARS therapy were split up into 3 subgroups, uneventful sessions (eventless, n = 16), sessions with
bleeding complications (bleeding, n = 3) and sessions complicated by device clotting (clotting, n = 6). For each individual session the
value obtained at around 2 h of MARS therapy was subtracted from the baseline value. For each parameter, the differences were compared
between subgroups by ANOVA and in case of significance Bonferroni group comparison was performed. ANOVA was only significant for
the parameter TT (b) and Lys 60′ (c). ∗Indicates significantly different subgroups at the P < .05 level, n = 19 (b) and 13 (c), respectively.
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(a) (b)
(c) (d)
Figure 5: Thromboelastography detects fibrinolysis during MARS:
Print outs of thromboelastography assessed during MARS session
1 in patient no. 2 which was complicated by bleeding after 2
hours of MARS therapy. Blood samples were obtained before (a)
1hour after (b) and 2 hours after (c) initiation of MARS. (d)
shows thromboelastography one hour after MARS was stopped
and substitution therapy was initiated. Grids and parameters are as
explained in Figure 1.
as in terms of response (decreased endogenous thrombin
potential and decreased peak; Figure 5(b)). After MARS, the
parameters recovered to baseline levels (Figure 6(b)).
4. Discussion
MARS treatment has been used in several thousand patients
worldwide. Initially it was reported to be effective and safe
and to improve surrogates such as bilirubin levels [8, 17–21],
encephalopathy [17, 22], and as well as ameliorate systemic,
renal and cerebral blood flow [17–19, 23–29]. Nevertheless,
preliminary data from the yet unpublished RELIEF multi
centre trial and meta-analysis [5] based on 4 randomized
controlled trials [17–19] reported no survival benefit of
MARS therapy.
Could it be that MARS efficacy failed because undesired
side effects jeopardized benefits? MARS therapy indeed
has been reported to worsen hepatic coagulopathy and
eventually cause bleeding complications [8–10]. Our actual
study confirms and extends these previous observations
by demonstrating clotting parameters such as INR, aPTT,
TT, plasma fibrinogen concentration, and platelet count, as
well as the functional parameters of thromboelastography
deteriorate during MARS therapy.
Could baseline screening help to identify patients at risk?
Similar to previous studies [8–10], we found that baseline
clotting parameters tend to be more pathologic in patients
developing bleeding complications. Age, INR and D-Dimer
level at baseline have been reported to significantly correlate
with bleeding complications during MARS [8], however,
so far no parameter or set of parameters have helped to
accurately identify patients at risk [8–10].
Herein we now addressed if patients at risk can be identi-
fied while MARS therapy is applied and if early intervention
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Figure 6: No indication for activation of the clotting system by
MARS: From a subset of MARS sessions (patient no. 2 and no. 4)
frozen plasma samples were available and parameters for thrombin
activation were determined. (a) Quantification of F1+2 fragments by
ELISA in plasma samples obtained before (prior) during and after
the MARS sessions, are presented as box plots. Baseline F1+2 values
were significantly above the cut-off value of 1.2 nmol/L (P < .05).
MARS therapy did not significantly influence F1+2 values over time.
(b) Estimation of the endogenous thrombin potential. Samples were
as in (a). Line plots present data as mean ± SD for the parameters
lag time, endogenous thrombin potential (ETP), maximal response
(peak) and the time until the peak is reached (time to peak), n = 8,
∗Indicates P < .05.
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might prevent clinically relevant bleeding episodes. We
found that bed-side thromboelastography reliably detected
hyperfibrinolysis in all sessions with bleeding episodes. Given
the small number of events (n = 3) we, however, could
not calculate predictive values. Although bed-side throm-
boelastography is considered to rapidly generate parameters,
in one out of two patients hyperfibrinolysis and severe
defibrination occurred so fast, that is, within the first hour
of MARS therapy, that fibrinolysis was only recognized by
thromboelastography when bleeding had already occurred
also clinically. Thromboelastography requires a clot to be
formed in the first place to detect fibrinolysis. If substitution
of InTeg activator by a more rapid agonist and complemen-
tation of the patient sample with factors such as fibrinogen
could accelerate detection of hyperfibrinolysis and be more
sensitive will have to be addressed in future studies.
Instead of simply identifying patients prone to bleeding,
targeting the underlying mechanism triggered by MARS
would be the desired therapeutic option. We found fibri-
nolysis in both patients who suffered form bleeding com-
plications, This suggests that plasminogen activation results
in hyperfibrinolysis and would thus be the main reason
for the bleeding complications. Uncontrolled plasminogen
activation is a recognized complication of extra corporal
devices involving foreign membranes [7]. Given the small
study population we, however, cannot rule out other mecha-
nisms to cause bleeding complications other than fibrinolysis
as reported by other studies. We, therefore, would not
recommend preemptive antifibrinolytic therapy for patients
with severely altered clotting parameters undergoing MARS
therapy.
Besides hyperfibrinolysis underlying thrombocytope-
nia, platelet dysfunction, dysfibrinogenaemia, disseminated
intravasal coagulation, reduced clearance of activated clot-
ting factors and endothelial dysfunction, common in patients
suffering from liver disease [6], certainly contribute to
bleeding complications. Extra corporal blood flow, blood
pumps, filter systems and bubble traps further aggravate such
disorders [7] and decrease in clotting factor VIII and von
Willebrand factor have been reported [9]. These findings
support aggravation of disseminated intravasal coagulation.
In contrast we found the F1+2 fragments, products released
upon conversion of prothrombin, to decrease during MARS
and the thrombin potential to decrease upon therapy.
Although this observation would argue against aggravation
of consumptive coagulopathy, clearance of F1+2 peptide by
MARS which uses a 45 kD cut-off membrane and factor
depletion triggered by consumptive coagulopathy could
explain our findings.
Whereas most alterations of clotting parameters must
be attributed to the MARS therapy itself, some alterations
might—at least in part—be explained by the application of
low-dose heparin. The prolonged thrombin time reported in
uncomplicated MARS sessions and sessions complicated by
device clotting might be caused by heparin.
Besides bleeding, device clotting complicatesMARS ther-
apy. We found that lack of thrombocytopenia and elevated
plasma fibrinogen concentrations predict clotting events
and that both platelet inhibition with epoprostenol and the
administration of unfractionated heparin could not prevent
filter clotting. If combining either anticoagulant or citrate
anticoagulation (as is used routinely for hemofiltration)
would prevent such events will have to be addressed in future
research.
In conclusion, our study shows that bleeding compli-
cations are a major concern of MARS therapy. Extended
baseline monitoring cannot accurately identify patients that
will develop bleeding complications. However, we found that
normal or increased platelet counts and elevated plasma fib-
rinogen concentrations at baseline allow predicting clotting
of the MARS filter system. Although close monitoring of
clotting parameters and especially monitoring by bed-side
thromboelastography can anticipate bleeding complications,
bleeding can still develop before clotting parameters become
available.
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